From 19th century ‘white blood’ observations and pathological anatomy to the discovery of BCR-ABL and imatinib, leukemia care ...
Assessing Algorithmic Fairness With a Multimodal Artificial Intelligence Model in Men of African and Non-African Origin on NRG Oncology Prostate Cancer Phase III Trials Recent advances in machine ...
Recent advancements in deep learning have transformed the analysis of blood cell images and the classification of leukemia. By employing complex neural network architectures, such as convolutional ...
Unlock the potential for faster, more comprehensive leukemia characterization with this webinar from Dana-Farber Cancer Institute expert Salvatore Benfatto. Acute leukemia (AL) is an aggressive form ...
BOSTON, September 22, 2025 — Researchers at Dana-Farber Cancer Institute have developed a groundbreaking diagnostic tool that could transform the way acute leukemia is identified and treated. The tool ...
Predictors of Oral Mucositis in Patients Receiving Hematopoietic Cell Transplants for Chronic Myelogenous Leukemia AML M5 represents an immunologically heterogeneous population similar to non-M5 AML ...
(a) Peripheral blood smear in a patient with the chronic phase of chronic myeloid leukemia (CML) before treatment; (b) Detection of BCR::ABL1 fusion gene, p210 by RNA sequencing; (c) Peripheral blood ...
Morning Overview on MSN
NUTM1-driven infant leukemia appears highly treatable, study finds
Infant leukemia linked to rearrangements of the NUTM1 gene has shown remarkably strong outcomes on current therapy in ...
Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from manageable conditions to fatal diseases.
Chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL) are types of blood cancer. They develop in types of white blood cells called B cells or T cells, or the precursors to these cells.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results